Cibc World Market Inc. Cuts Stake in IQVIA Holdings Inc. $IQV

Cibc World Market Inc. decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 34.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 20,983 shares of the medical research company’s stock after selling 10,812 shares during the period. Cibc World Market Inc.’s holdings in IQVIA were worth $4,730,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after purchasing an additional 159,899 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after purchasing an additional 24,453 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of IQVIA by 1.2% in the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after purchasing an additional 41,643 shares in the last quarter. Boston Partners purchased a new stake in shares of IQVIA in the 3rd quarter valued at $676,698,000. Finally, Artisan Partners Limited Partnership boosted its stake in shares of IQVIA by 4.9% in the 3rd quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after purchasing an additional 161,085 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 0.1%

Shares of NYSE IQV opened at $183.56 on Monday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 12 month low of $147.62 and a 12 month high of $247.04. The firm has a market capitalization of $30.64 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 1.57 and a beta of 1.21. The firm has a fifty day simple moving average of $172.12 and a two-hundred day simple moving average of $194.79.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same period in the prior year, the business earned $2.70 EPS. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a stock buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research reports. HSBC set a $210.00 price objective on shares of IQVIA in a research note on Wednesday. Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research report on Friday, March 6th. Evercore reissued an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Finally, Mizuho set a $215.00 price target on shares of IQVIA in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, IQVIA has an average rating of “Buy” and an average target price of $224.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.